• Patients must be =\< 50 years of age at the time of enrollment

• Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification are eligible to enroll on the study based upon stage, group, and age, as below. FOXO1 fusion status must be determined by week 4 (day 28) of therapy. RMS types included under embryonal RMS (ERMS) include those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the 2020 World Health Organization (WHO) Classification as ERMS (classic, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant). Classification of alveolar RMS (ARMS) in the 2020 WHO Classification is the same as in the ICR and includes classic and solid variants

‣ ERMS

∙ Stage 4, group IV, \>= 10 years of age

⁃ ARMS

∙ Stage 4, group IV Patients will be eligible to remain on protocol therapy based upon stage, group, and age

• Bone marrow metastatic disease is based on morphologic evidence of RMS based on hematoxylin and eosin (H\&E) stains. In the absence of morphologic evidence of marrow involvement on H\&E, patients with bone marrow involvement detected ONLY by flow cytometry, reverse transcriptase (RT)-polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or immunohistochemistry will NOT be considered to have clinical bone marrow involvement for the purposes of this study

• Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/sex as follows (must be performed within 7 days prior to enrollment):

‣ Age; Maximum serum creatinine (mg/dL)

⁃ 1 month to \< 6 months; 0.4 mg/dL (male); 0.4 mg/dL (female)

⁃ 6 months to \< 1 year; 0.5 mg/dL (male); 0.5 mg/dL (female)

⁃ 1 to \< 2 years; 0.6 mg/dL (male); 0.6 mg/dL (female)

⁃ \>= 16 years; 1.7 mg/dL (male); 1.4 mg/dL (female)

• Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment)

‣ If there is evidence of biliary obstruction by tumor, then total bilirubin must be \< 3 x ULN for age

• All patients and/or their parents or legal guardians must sign a written informed consent

• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met